Erika Hamilton, MD, FASCO· @ErikaHamilton9 · X·· 1 天前评分70
正文 · 原文
#FINER fulvestrant +/- ipatasertib (AKTi)
45% of pts were pathway altered
PFS lengthened in ITT HR 0.68
and AKT altered cohorts HR 0.55
93% diarrhea, pretty high G2/3 rates
#ESMO26 #ESMOAmbassadors
29 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：Erika Hamilton, MD, FASCO · x.com